MindMed to Participate in June Conferences
Get Alerts MNMD Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:
-
BIO International Convention 2024
- Panel Name: Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
- Date and Time: Tuesday, June 4, 2024 at 4:15 pm PDT
- Location: San Diego, CA
-
Jefferies 2024 Global Healthcare Conference
- Format: 1x1 investor meetings only
- Dates: June 5-6, 2024
- Location: New York, NY
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528659571/en/
For Media: [email protected]
For Investors: [email protected]
Source: Mind Medicine Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diamond K Gypsum Launches New Agricultural Water Management Technologies for Improved Irrigation Water Efficiency and Drought Resilience
- Park Aerospace Corp. Announces Date of First Quarter Earnings Release and Conference Call
- Handmade Patriotic Quilts Bring Comfort, Gratitude, and Hope to Future Combat-Wounded Veterans
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share